Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HM97662 in Advanced or Metastatic Solid Tumors
NCT05598151Phase 1Active, not recruiting
- Sponsor
- Hanmi Pharmaceutical
- Start
- Jan 2023
- Primary completion
- Jan 2028
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 1, randomised, open-label trial of HM97662 in solid tumor, sponsored by Hanmi Pharmaceutical. Primary endpoints: Dose-Limiting Toxicities at 28 days and Adverse Events. Started Jan 2023; status: active, not recruiting.
02
Drugs
HM97662
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05598151.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05598151.